Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 10/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 10/20 | 0.40 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.34 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1969020 | 0.93 | HCRTR1 (0.42) | HCRTR1HCRTR2PDE4BLTC4SMAPT | |
| SCHEMBL1973040 | 0.93 | HCRTR1 (0.38) | HCRTR1HCRTR2TP53HTTPDE4B | |
| SCHEMBL1967942 | 0.91 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL1969724 | 0.90 | HCRTR1 (0.42) | HCRTR1HCRTR2OXTRAVPR1ATP53 | |
| SCHEMBL2404306 | 0.89 | OXTR (0.38) | HCRTR1HCRTR2OXTRAVPR1ATP53 | |
| SCHEMBL2406784 | 0.88 | HCRTR1 (0.39) | HCRTR1HCRTR2TP53 | |
| SCHEMBL1967810 | 0.86 | AKR1C3 (0.39) | HCRTR1HCRTR2NPSR1LTC4S | |
| SCHEMBL1968038 | 0.85 | HCRTR1 (0.33) | HCRTR1HCRTR2PDE4BLTC4S | |
| SCHEMBL2404671 | 0.84 | HCRTR1 (0.43) | HCRTR1HCRTR2OXTRAVPR1APDE4B | |
| SCHEMBL1970670 | 0.84 | HCRTR1 (0.44) | HCRTR1HCRTR2PDE4BMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR1 2/4885HCRTR2 1/4885OXTR 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.